Researchers report that a drug commonly used to treat diabetes¹ may also retard²（延迟，阻止） the growth of fluid-filled cysts（囊肿） of the most common genetic³ disorder⁴, polycystic kidney（多囊肾） disease. PKD does not discriminate⁵ by gender⁶ or race and affects one in 1,000 adults worldwide. Researchers from the schools of Science and Medicine at Indiana University-Purdue University Indianapolis and colleagues from the Mayo Clinic report this month in the online peer-reviewed journal PPAR Research that pioglitazone appears to control the growth of PKD cysts.

Using a rat model that has the same genetic mutation⁷ as a form of human PKD, the two research groups independently tested a pioglitazone treatment regimen and found that it slowed down both kidney and liver cyst growth by inhibiting⁸ a chloride（氯化物） channel in the cells of these organs.

Normally pioglitazone works by making the body more sensitive to its own insulin. However, in studying why this class of drugs causes fluid retention⁹, Bonnie L. Blazer-Yost, Ph.D., professor of biology at the IUPUI School of Science and corresponding author of the new study, serendipitously¹⁰（意外收获） found that it also inhibits¹¹ a chloride channel.

"We thought that since this class of drugs inhibits the body's chloride channels, then it would be a good candidate to treat PKD, a disease in which excessive chloride and water are transported into the cysts of the kidneys and the liver causing them to expand," said Blazer-Yost, Ph.D.

A normal kidney is the size of a fist. A polycystic kidney is the size of a football. Currently there is no cure for PKD and therapy options are limited. Organ transplantation is the most common treatment.

"The idea of using a chloride channel inhibitor to treat PKD is not new. What is new is our finding that an insulin sensitizing agent like piogltiazone inhibits chloride channels. The finding that pioglitazone, which has already been approved by the Food and Drug Administration for diabetes, can halt cyst progression and may be an effective and well-tolerated treatment for this chronic¹² disease, is exciting. Confirmation¹³ of these results in other animal models of PKD would be a useful next step.

"We know from long-term experience that this drug has a good safety profile. Strategies that minimize adverse¹⁴ events are important when considering treatments for a chronic disease such as PKD," said Blazer-Yost, a physiologist¹⁵ who hopes that human trials of pioglitazone therapy for PKD can be conducted in the near future.